Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor

Inclusion Criteria: * • Healthy male or female volunteers, aged between 18 and 45 years; * Availability to undergo all procedures throughout the study period; * Provide free and informed consent to participate in the study. Exclusion Criteria: * Participation in clinical trials within the last year * Participation in cohort studies * Diagnosis of concomitant infections or diseases that may affect immunity, including active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasms, and autoimmune diseases; * Current or previous diagnosis or family history of ARF, chorea, obsessive-compulsive disorder, or glomerulonephritis; * Current or previous diagnosis of heart diseases; * Severe asthma or chronic obstructive pulmonary disease (COPD); * Abnormal neurological clinical assessment, especially chorea; * Use of treatments that may affect immunity in the last four weeks, including immunomodulators, corticosteroids (only systemic use for two weeks or more), or antineoplastic agents; * Use of treatments that may affect heart valves in the last four weeks or planned during the study period, including fenfluramine and dexfenfluramine; * Renal insufficiency determined by estimated creatinine clearance below 45 ml/min/1.73m²; * History of intolerance or allergy to any component of the study product, including antigen or adjuvant; * Presence of valve abnormalities or alterations in cardiac anatomy as defined by echocardiogram; * Altered electrocardiogram; * Evidence …